BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 27052877)

  • 1. Population Pharmacokinetics of Oral Topotecan in Infants and Very Young Children with Brain Tumors Demonstrates a Role of ABCG2 rs4148157 on the Absorption Rate Constant.
    Roberts JK; Birg AV; Lin T; Daryani VM; Panetta JC; Broniscer A; Robinson GW; Gajjar AJ; Stewart CF
    Drug Metab Dispos; 2016 Jul; 44(7):1116-22. PubMed ID: 27052877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral topotecan: Bioavailability, pharmacokinetics and impact of ABCG2 genotyping in Chinese patients with advanced cancers.
    Li N; Song Y; Du P; Shen Y; Yang J; Gui L; Wang S; Wang J; Sun Y; Han X; Shi Y
    Biomed Pharmacother; 2013 Oct; 67(8):801-6. PubMed ID: 24074809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier.
    Poller B; Wagenaar E; Tang SC; Schinkel AH
    Mol Pharm; 2011 Apr; 8(2):571-82. PubMed ID: 21309545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics and pharmacogenomics of apixaban in Japanese adult patients with atrial fibrillation.
    Ueshima S; Hira D; Kimura Y; Fujii R; Tomitsuka C; Yamane T; Tabuchi Y; Ozawa T; Itoh H; Ohno S; Horie M; Terada T; Katsura T
    Br J Clin Pharmacol; 2018 Jun; 84(6):1301-1312. PubMed ID: 29457840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of ABCG2 genotype on the oral bioavailability of topotecan.
    Sparreboom A; Loos WJ; Burger H; Sissung TM; Verweij J; Figg WD; Nooter K; Gelderblom H
    Cancer Biol Ther; 2005 Jun; 4(6):650-8. PubMed ID: 15908806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors.
    Zamboni WC; Bowman LC; Tan M; Santana VM; Houghton PJ; Meyer WH; Pratt CB; Heideman RL; Gajjar AJ; Pappo AS; Stewart CF
    Cancer Chemother Pharmacol; 1999; 43(6):454-60. PubMed ID: 10321504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors.
    Reddick SJ; Campagne O; Huang J; Onar-Thomas A; Broniscer A; Gajjar A; Stewart CF
    Cancer Chemother Pharmacol; 2019 Oct; 84(4):829-838. PubMed ID: 31392390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased delivery of chemotherapy to the vitreous by inhibition of the blood-retinal barrier.
    Pascual-Pasto G; Olaciregui NG; Opezzo JAW; Castillo-Ecija H; Cuadrado-Vilanova M; Paco S; Rivero EM; Vila-Ubach M; Restrepo-Perdomo CA; Torrebadell M; Suñol M; Schaiquevich P; Mora J; Bramuglia GF; Chantada GL; Carcaboso AM
    J Control Release; 2017 Oct; 264():34-44. PubMed ID: 28830790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.
    Kruijtzer CM; Beijnen JH; Rosing H; ten Bokkel Huinink WW; Schot M; Jewell RC; Paul EM; Schellens JH
    J Clin Oncol; 2002 Jul; 20(13):2943-50. PubMed ID: 12089223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overlapping functions of ABC transporters in topotecan disposition as determined in gene knockout mouse models.
    Tiwari AK; Zhang R; Gallo JM
    Mol Cancer Ther; 2013 Jul; 12(7):1343-55. PubMed ID: 23635651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients.
    Yamagata T; Kusuhara H; Morishita M; Takayama K; Benameur H; Sugiyama Y
    Drug Metab Dispos; 2007 Jul; 35(7):1142-8. PubMed ID: 17446265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetic analysis of topotecan in pediatric cancer patients.
    Schaiquevich P; Panetta JC; Iacono LC; Freeman BB; Santana VM; Gajjar A; Stewart CF
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6703-11. PubMed ID: 18006771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Boosting bioavailability of topotecan: what do we gain?
    Hudes G
    J Clin Oncol; 2002 Jul; 20(13):2918-9. PubMed ID: 12089219
    [No Abstract]   [Full Text] [Related]  

  • 14. Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): monocentric study.
    Tandia M; Mhiri A; Paule B; Saffroy R; Cailliez V; Noé G; Farinotti R; Bonhomme-Faivre L
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):759-766. PubMed ID: 28289864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pelitinib (EKB-569) targets the up-regulation of ABCB1 and ABCG2 induced by hyperthermia to eradicate lung cancer.
    To KK; Poon DC; Wei Y; Wang F; Lin G; Fu L
    Br J Pharmacol; 2015 Aug; 172(16):4089-106. PubMed ID: 25988710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues.
    Lin F; Marchetti S; Pluim D; Iusuf D; Mazzanti R; Schellens JH; Beijnen JH; van Tellingen O
    Clin Cancer Res; 2013 Apr; 19(8):2084-95. PubMed ID: 23461902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitation of the impact of CYP3A5 A6986G polymorphism on quetiapine pharmacokinetics by simulation of target attainment.
    Shilbayeh SA; Sy SK; Melhem M; Zmeili R; Derendorf H
    Clin Pharmacol Drug Dev; 2015 Sep; 4(5):387-94. PubMed ID: 27137148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice.
    Zhang S; Wang X; Sagawa K; Morris ME
    Drug Metab Dispos; 2005 Mar; 33(3):341-8. PubMed ID: 15608138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transporter genes ABCG2 rs2231142 and ABCB1 rs1128503 polymorphisms and atorvastatin response in Chilean subjects.
    Prado Y; Zambrano T; Salazar LA
    J Clin Pharm Ther; 2018 Feb; 43(1):87-91. PubMed ID: 28833323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCRP/ABCG2 and high-alert medications: Biochemical, pharmacokinetic, pharmacogenetic, and clinical implications.
    Hira D; Terada T
    Biochem Pharmacol; 2018 Jan; 147():201-210. PubMed ID: 29031817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.